网站首页新闻动态 > 热烈祝贺欣生源2020年再次签约SeaRunHoldings中国区独代
热烈祝贺欣生源2020年再次签约SeaRunHoldings中国区独代
更新时间:2019-08-20 点击量:2702

深圳欣生源生物科技有限公司再次签约美国Sea Run Holdings公司中国区独代授权商(Sole Agency Agreement)。我司已同美国Sea Run Holdings公司签约合作多年,共同合作研究开发再生医学研究试剂,力争为广大的科研工作者提供更好,更专业的服务。

 

Salmon fibrinogen (SEA-133) and fibrin ECM 鲑鱼蛋白原

  • Excellent proliferation of stem cells and retention of “stemness” (Zhou et al. Stem Cell Trans. Medicine. 2017;6(5):1412-1423)
  • Superior to Matrigel for neurite outgrowth and neuronal cell growth (Ju et al. Biomaterials. 2007 April; 28 (12): 2097-2108)
  • More efficient ECM (60-188%) than human derived fibrin gels for angiogenesis. (Sieminski et al.  2004. J Biomater Sci Polym. Ed 15(2):237-42)
  • Slower gel degradation in vitro and in vivo
  • Selection and growth of tumorigenic cells (Liu J et al. Nat. Mater. 2012 Jul 1, 11(8):734-41)

Salmon thrombin (SEA-135)  鲑鱼凝血酶

  • Optimal polymerization of salmon fibrinogen
  • Significant and sustained analgesia for pain studies (Weisshaar et al. 2011 Biomaterials:9738-9746)
  • Potential alternative for opioids.
  • Blocks disruption of blood-brain barrier. (Smith et al. 2016. BioMaterials 80: 96-105).